Category Archives: Myocardial Infarction

MedicalResearch.com Interview with: Haider Aldiwani, MD Fellow in Internal Medicine and C. Noel Bairey Merz, MD, FACC, FAHADirector Barbra Streisand Womens Heart Center Smidt Heart Institute, Cedars-Sinai Medical Center Los Angeles, CA, 90048 MedicalResearch.com: What is the background for this study? Response: Cardiovascular disease is the leading cause of death in women in the United States. Continue reading →

INDIANAPOLIS, Feb. 21, 2020 /PRNewswire/ --The U.S. Continue reading →

Growth forecast on Thrombolytic Therapy Market size | Industry Segment by Applications (Acute Myocardial Infarction, Pulmonary Embolism, Deep Vein Thrombosis, Blocking the Catheter, Acute Ischemic Stroke, Demand from the acute myocardial infarction accounts for the largest market share and being 36.9% in 2019), by Type (Drug Treatment, Surgical Treatment, Other Treatment, Drug treatment is the most commonly used type and with about 89.15% market share in 2019), Regional Outlook, Market Demand, Latest Trends, Thrombolytic Therapy Industry Share & Revenue by Manufacturers, Company Profiles, Growth Forecasts 2025. The growth trajectory of the Global Thrombolytic Therapy Market over the assessment period is shaped by several prevalent and emerging regional and global trends, a granular assessment of which is offered in the report. Major Company Profiles Covered in This Report: Request Sample Copy of this Report @ https://www.aeresearch.net/request-sample/95793 The key points of the Thrombolytic Therapy Market report: Thrombolytic Therapy Market Statistics by Types: Thrombolytic Therapy Market Outlook by Applications: Some of the major objectives of this report: Key Questions Answered: Request Customization on This Report @ https://www.aeresearch.net/request-for-customization/95793 Continue reading →

February 20, 2020 16:05 ET | Source: Baudax Bio, Inc. ANJESO Is The Only Approved 24-Hour, Intravenous COX-2 Preferential NSAID that Offers Once-Daily Dosing U.S.Commercial Launch Planned to Commence in Late April or Early May 2020 Management to Host Conference Call and Webcast Today at 4:30 p.m Continue reading →

PURPOSE: Following a favourable pilot trial using a single-bolus of ciclosporin, it has been unclear why two large studies (CYCLE and CIRCUS) failed to prevent reperfusion injury and reduce infarct size in STEMI (ST elevationmyocardial infarction). The purpose of this study was to assess the effect of ciclosporin onmyocardialinjury, LV-remodelling, and lymphocyte kinetics in patients with acute STEMI undergoing primary PCI. Continue reading →

Heart disease is the primary cause of death worldwide, principally because the heart has minimal ability to regenerate muscle tissue. Myocardial infarction (heart attack) caused by coronary artery disease leads to heart muscle loss and replacement with scar tissue, and the heart's pumping ability is permanently reduced. Continue reading →

Over the 13-year period ending in 2016, revascularization procedural volumes have dropped by half, although the percentage of percutaneous coronary intervention (PCI) procedures done for myocardial infarction (MI) have more than doubled, a new administrative study shows. During the same period, risk-adjusted in-hospital mortality rates after coronary artery bypass grafting (CABG) have also improved, whereas in PCI for ST-segment elevation myocardial infarction (STEMI), they've hovered stubbornly around 5%. Continue reading →

HS:I have a deep-seated feeling within my core that how one takes care of a human is not proprietary. We should share that information. Continue reading →

Background Coexistence of cancer and cardiovascular disease is increasingly frequent, but nationwide data covering cancer patients withmyocardial infarction(MI) are scarce. Continue reading →

The artificial heart is very effective as a bridge to transplant, but the number of people that can be saved with human hearts is limited. Continue reading →